Sunbird Software

Sunbird Bio has developed a proprietary blood-based diagnostics platform capable of directly detecting and quantifying disease-specific proteins that aggregate in the brain—such as amyloid beta, tau, alpha synuclein, and TDP43—enabling earlier and more accurate diagnosis of Alzheimer’s disease, Parkinson’s disease, other neurological disorders, and early-stage cancer. The company claims its technology overcomes limitations of current diagnostics by providing direct detection from a simple blood draw rather than relying on surrogate markers or invasive procedures. As of mid–2025 the company was expanding clinical studies with recent funding but had not yet reported pivotal trial results or commercial launch data